Reduced pericardial levels of endostatin correlate with collateral development in patients with ischemic heart disease  by Panchal, Vipul R. et al.
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OBJECTIVES We investigated whether pericardial levels of a pro-angiogenic factor (vascular endothelial
growth factor, VEGF) or an anti-angiogenic factor (endostatin) related to the presence of
coronary collateral circulation in patients with significant coronary artery disease (CAD).
BACKGROUND Coronary collateralization favorably alters the prognosis of patients with occlusive CAD. The
specific factors that mediate and maintain collateral formation in coronary vessel occlusion are
yet to be identified.
METHODS Coronary angiograms from 39 patients undergoing coronary artery bypass surgery were
evaluated for the absence of collaterals (n 20) or the presence of Rentrop classification grade
3 collaterals (n  19). Pericardial fluid samples were obtained at the time of surgery and were
assayed for the VEGF and endostatin by enzyme-linked immunosorbent assay comparing the
two groups of patients.
RESULTS Vascular endothelial growth factor levels were not significantly different between the groups
(28.86 4.67 pg/ml vs. 24.39 3.08 pg/ml, p 0.43). However, pericardial fluid endostatin
levels were nearly 40% lower in patients with grade 3 collateralization compared with those
lacking angiographic evidence of collaterals (15.17  1.87 ng/ml vs. 24.25  2.08 ng/ml,
p  0.0025).
CONCLUSIONS Pericardial fluid levels of endostatin, but not VEGF, are associated with the presence or
absence of collaterals in patients with CAD. These data suggest that the angiogenesis
inhibitor endostatin levels may locally modulate coronary collateral formation. (J Am Coll
Cardiol 2004;43:1383–7) © 2004 by the American College of Cardiology Foundationg
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phe presence of coronary collateralization improves the
rognosis of patients with obstructive coronary artery dis-
ase (CAD). Collaterals limit infarct size and improve
entricular function and overall perfusion in ischemic myo-
ardium (1–3). The development of coronary collaterals
ppears to be initiated by an occlusive event resulting in
pening of preexisting anastomotic channels through in-
rease in shear forces and pressure or by formation of novel
apillary sprouts (angiogenesis) from chronic ischemia (4).
ubsequent maintenance and maturation of these vessels
arteriogenesis) is believed to be mediated by a balance of
ro-angiogenic and anti-angiogenic factors that favor neo-
ascularization (4).
Assessment of these substances is difficult as they are
roduced locally in ischemic cardiac tissue and are lower in
ystemic circulation because of dilution upon washout (3).
oronary sinus and arterial samples can demonstrate a small
step-up” in concentration of factors produced in the myo-
ardium (5), but are subject to the same washout influences
nd may not necessarily demonstrate a gradient (6,7).
Pericardial fluid analysis provides a modality that may
eflect the local angiogenic milieu more accurately (8). For
xample, angiogenic substances such as basic fibroblast
From the *Department of Medicine, Krannert Institute of Cardiology; and
Department of Surgery, Thoracic Surgery Section, Indiana University School of
edicine, Indianapolis, Indiana.
Manuscript received September 15, 2002; revised manuscript received September4, 2003, accepted October 7, 2003.rowth factor and vascular endothelial growth factor
VEGF) are more concentrated in pericardial fluid than in
erum and are elevated in patients with ischemic heart
isease (9,10). In addition, pericardial fluid has been shown
o accelerate vascular smooth muscle cell growth and induce
ndothelial cell apoptosis, suggesting that substances in
ericardial fluid are active and may exert physiologic effects
ocally (11,12).
Our goals in the present study were to measure VEGF
nd endostatin levels in the pericardial fluid of patients with
ignificant obstructive CAD and to investigate their relation
o the presence of coronary collaterals.
Vascular endothelial growth factor is an angiogenic
rowth factor that is implicated in both normal angiogenesis
development, wound repair) and abnormal angiogenesis
e.g., tumor growth and retinopathy) (13). It is expressed
arly in patients with acute myocardial ischemia and impli-
ated in neovascularization (14,15). Recent research has
hown that VEGF can enhance therapeutic angiogenesis in
xperimental models (16).
Endostatin is a potent inhibitor of angiogenesis that was
rst isolated from in vitro murine hemangioendothelioma
ell line cultures. It is an endogenous 20kD protein that is
he noncollagenous carboxy-terminal fragment of collagen
VIII produced by proteolytic cleavage (17). Elastase,
athepsin L, and various other enzymes have been shown to
roduce endostatin from collagen XVIII (18).
Endostatin exhibits potent anti-angiogenic activity by
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Endostatin and Coronary Collateralization April 21, 2004:1383–7nhibiting proliferation and migration of endothelial cells in
ddition to inducing endothelial cell apoptosis (17,19). The
pecific receptors and signaling cascades for its mechanism
f action are yet to be defined. A variety of malignancies are
ssociated with elevated circulating serum endostatin levels.
ndostatin has been shown to inhibit the growth of many
ypes of murine cancers by inhibiting tumor angiogenesis
nd inducing dormancy. Recently, a phase I clinical trial for
reatment of solid tumors has been published demonstrating
afety and minor antitumor activity (20).
ETHODS
his study was approved by the Indiana University Institu-
ional Review Board. Patients were consecutively enrolled
nd informed consent was obtained before cardiac surgery.
atient selection. We reviewed the coronary angiograms
f patients serially undergoing coronary artery bypass graft-
ng (CABG) and assessed for coronary collateralization
sing the classification scale described by Rentrop et al. (21).
his scale ranges from grade 0 (representing absence of
ontrast filling an epicardial vessel) to grade 3 (complete
lling of the epicardial vessel by a contralateral artery).
atients were included if they had significant obstructive
oronary disease (70% stenosis) in at least two vessels
equiring CABG and could be stratified into either one of
he following two groups: the first group consisted of
atients without evidence of coronary collateralization
grade 0, n  20); the second consisted of patients demon-
trating the highest degree of coronary collateralization
grade 3, n  19).
Major exclusion criteria consisted of prior CABG, evi-
ence of ongoing malignancy or neoplasm, infection, and
oncomitant valvular disease requiring surgery.
actor measurements. Vascular endothelial growth factor
nd endostatin levels were determined by enzyme-linked
mmunosorbent assay according to the manufacturer’s in-
tructions. Briefly, the pericardial fluid samples were col-
ected during cardiac surgery at the time of pericardiotomy.
he fluid was centrifuged to separate debris and then frozen
t70°C for subsequent analysis. Factors were measured by
nzyme-linked immunosorbent assay (VEGF: R & D
ystems, Minneapolis, Minnesota, sensitivity 1 pg/ml; en-
ostatin: Cytimmune, College Park, Maryland, sensitivity
.953 ng/ml). The absorbance was measured by optical
ensitometry at 450 nm.
ata collection and statistical analysis. Clinical data were
ollected by chart review. Categorical demographic data
ere compared by Fisher exact test. Continuous variables
Abbreviations and Acronyms
CABG coronary artery bypass grafting
CAD  coronary artery disease
VEGF  vascular endothelial growth factorre presented as the mean  SEM, and compared bytudent t test and multivariate stepwise logistic regression.
ll probability values are two-tailed.
ESULTS
he patient demographics in the first group with absence of
ollateral development (grade 0) and with the greatest degree
ollateral development (grade 3) are presented in Table 1. As
xpected, there was a high prevalence of coronary risk factors in
oth groups including hypertension, smoking, and hyperlipid-
mia. No significant differences in patient characteristics were
vident between groups, although a trend toward more men
nd younger patients was noted in the collateral group. A
wo-way analysis of variance (ANOVA) using both gender and
ollateral grade as grouping factors revealed no evidence of
eneral gender-related effect on pericardial fluid endostatin
evels (F  0.3, p  0.578).
The clinical presentation of patients before surgery and
uid collection are presented in Table 2. This demonstrated
heterogeneous group comprised of patients with either
table angina or recent acute coronary syndromes (within 24
o 48 h). Both syndromes were similarly represented in both
roups.
The extent of CAD in the patient groups is characterized
n Table 3. The ischemic burden was similar in both patient
roups. The number of diseased vessels with 70% or greater
iameter stenosis, grafts required for revascularization, ejec-
ion fraction, and coronary vessels involved were not differ-
nt between groups with the exception of more right CAD
n the collateral group (p  0.05).
able 1. Patient Demographics
Grade 0
n  20
Grade 3
n  19 p
ge (yrs) 65.4  2.1 60.2  2.6 0.13 ns
ales (n) 12/20 17/19 0.07 ns
iabetes (n) 13/20 8/19 0.21 ns
ypertension (n) 18/20 15/19 0.41 ns
mokers (n) 14/20 16/19 0.45 ns
yperlipidemia (n) 15/20 18/19 0.18 ns
eripheral arterial
occlusive disease (n)
10/20 7/19 0.52 ns
nd-stage renal disease 4/20 0/19 0.11 ns
s  not significant.
able 2. Clinical Presentation
Grade 0
n  20
Grade 3
n  19 p
revious MI (n) 7/20 9/19 0.52 ns
table angina 9/20 8/19 0.97 ns
cute coronary syndrome* 11/20 12/19 0.75 ns
nzyme positivity† 9/21 5/19 0.32 ns
Includes unstable angina and myocardial infarction. †Elevation in troponin I or
reatine kinase-MB fractions.MI  myocardial infarction; ns  not significant.
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April 21, 2004:1383–7 Endostatin and Coronary CollateralizationAll patients in the grade 3 collateral group had at least
ne vessel subtotally or completely occluded, in contrast to
he grade 0 group, which evidenced only one such patient
p  0.0001). This is consistent with previous reports that
ote the need for transient or permanent coronary vessel
cclusion as a stimulus for growth factor modulation and
ollateral formation (22,23).
Vascular endothelial growth factor and endostatin levels
ith respect to gender, diabetes, acute coronary syndromes,
nd ejection fraction are shown in Figure 1. There were no
tatistical differences in these characteristics for both factors.
nzymatic evidence of myocardial necrosis, age, peripheral
able 3. Extent of Coronary Artery Disease
Grade 0
n  21
Grade 3
n  19 p
umber of diseased
vessels 70%
2.5  0.1 2.7  0.1 0.13 ns
umber of grafts required 3.2  0.2 3.3  0.2 0.83 ns
ccluded coronary
arteries (n)
1/20 19/19 0.001 *
jection fraction % 45.0  3.5 38.3  4.0 0.22 ns
eft main disease 50% 5/20 6/19 0.73 ns
eft anterior descending
artery disease 70%
16/20 18/20 0.34 ns
eft circumflex artery
disease 70%
12/20 13/20 0.74 ns
ight coronary artery
disease 70%
15/20 19/19 0.05 *
Denotes statistical significance.
ns  not significant.
igure 1. Vascular endothelial growth factor (VEGF) and endostatin leve
ellitus (DM), acute coronary syndrome (ACS) (present or absent), andifferences shown in either VEGF or endostatin with respect to any of these farterial occlusive disease, and extent of CAD (2-vessel vs.
-vessel disease) also demonstrated no differences in the
evels of these factors (data not shown).
Factor comparison based upon collateral grade revealed that
EGF was no different between the two groups. However,
ericardial fluid endostatin levels were found to be approxi-
ately 40% lower in patients with collaterals in comparison to
hose without (15.17  1.87 vs. 24.25  2.08, p  0.0025)
Fig. 2).
To identify determinants of collateral growth, multivari-
te stepwise logistic regression analysis was performed with
ollateral grade (0 or 3) as the outcome. Several character-
stics were evaluated, including various demographic char-
cteristics, gender, acute coronary syndrome/myocardial in-
arction, and endostatin levels.
In this multivariate analysis, only pericardial fluid en-
ostatin level was found to be predictive. The odds ratio for
ndostatin level was 0.88 (95% confidence interval 0.81 to
.97), p  0.0001.
Subsequent analysis of a subset of patients with at least
ne subtotally and totally occluded artery who had no
yocardial infarction demonstrated a similar difference in
ericardial fluid endostatin levels (9.09  2.18 ng/ml grade
vs. 22.33  4.21 ng/ml grade 0, p  0.03).
ISCUSSION
his study is the first to demonstrate a correlation between the
ericardial levels of an anti-angiogenic factor with coronary
patients grouped with respect to gender, presence or absence of diabetes
on fraction (EF) (35% or 35%). There are no statistically significantls in
ejectictors.
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Endostatin and Coronary Collateralization April 21, 2004:1383–7ollateral development in patients. Our data demonstrate that
ericardial fluid endostatin is about 40% lower in patients with
obust coronary collateral development than in patients with-
ut collaterals. This finding may, in part, explain differential
ngiogenic responses to ischemia in certain patients.
In addition, all patients in the collateral group exclusively
ad at least one occluded epicardial vessel. It is well
stablished that vessel occlusion or severe stenosis is a potent
timulus for collateral formation; however, in the context of
ur study, it can be postulated that such occlusion signals
he local downregulation of anti-angiogenic “tone” as a
relude to the formation of collateral vessels.
The levels of endostatin measured in this study are consis-
ent with concentrations known to be inhibitory to endothelial
ells in vitro. Furumatsu et al. (24) demonstrated that endosta-
in specifically inhibited proliferation of human umbilical vein
ndothelial cells at concentrations of 1 ng/ml, 10 ng/ml, and
00 ng/ml in a dose-dependent manner and also inhibited
ttachment of endothelial cells to collagen I. More impor-
igure 2. Vascular endothelial growth factor (VEGF) and endostatin levels
n patients without angiographically visible collaterals (Rentrop grade 0)
ersus those with robust angiographically visible colaterals (Rentrop grade
). Although VEGF is not different between these populations, endostatin
s reduced by 40%, with strong significance, in the patient group that has
anifested the growth of prominent collaterals.antly, similar inhibitory effects were also observed in endothe- iial cells that were stimulated by angiogenic growth factors such
s VEGF and basic fibroblast growth factor (bFGF) (25),
uggesting that endostatin’s potent effects may be mediated by
ignaling pathways that are independent of the VEGF and
FGF signaling. Assuming that pericardial fluid concentra-
ions approximate those in the myocardial interstitium, we can
ostulate that the dose-related inhibitory effects of endostatin
t the levels measured are physiologically relevant, and may be
ore pronounced in the group of patients without collateral
evelopment (grade 0) as their pericardial fluid levels were
ignificantly higher. In our analysis, the odds ratio for endosta-
in levels was 0.88.
It is of interest that VEGF was not significantly different
etween the two groups and suggests that the process of
rteriogenesis and maturation of collateral channels may not
ecessarily be dependent on persistent VEGF elevation. As
iscussed earlier, the in vitro inhibitory action of endostatin
ersists despite VEGF stimulation (25). Vascular endothe-
ial growth factor is clearly important in angiogenesis and is
pregulated in response to acute ischemia. However, its role
n collateral development is less understood. It has been
eported that monocytes derived from patients with collat-
rals exhibit greater VEGF production; however, this was
oted in response to acute hypoxia (26).
These data suggest the hypothesis that the process of
eovascularization in patients with ischemic heart disease
epends on repression of anti-angiogenic influences, such as
ndostatin, to facilitate neovascularization. This may help
xplain the limited clinical success in recent attempts at
yocardial angiogenesis (16). Modulation of local anti-
ngiogenic factors represents an important aspect in future
tudies of angiogenesis.
tudy limitations. There are several limitations to the
resent study. First, there were no control patients without
oronary disease for comparison. Serum samples were not
vailable for study, although “washout” and dilution of these
actors in systemic circulation limit its utility.
Our study stratifies patients based on angiographically
vident collaterals and does not account for inherent limits
n detecting vessels smaller than 200 m, such as recruitable
ollaterals. These are thought to be pre-existing anastomotic
hannels that are not angiographically evident until matu-
ation through arteriogenesis. However, these vessels are
unctionally evident on coronary pressure wire measure-
ents of collateral flow index and other modalities.
The present findings show a correlation of reduced endosta-
in levels with collateral development but do not prove causa-
ion. Experimental models that have been used to demonstrate
he inhibitory effects of angiostatin on coronary collateral
ormation (22) may allow for demonstration of the causal effect
f endostatin on coronary collateral formation. Furthermore,
uture studies may also examine whether inhibition of pericar-
ial or interstitial endostatin with an antibody or similarnhibitor may improve therapeutic angiogenesis.
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